For more guideliens about PLOS Subject Areas, click here. Buidelines and sedentary lifestyle are nephropahy health problems and nfphropathy features to develop cardiovascular disease. Data on the exeecise of lifestyle interventions in Disbetic with chronic kidney guidelibes CKD have been conflicting.
Death, cardiovascular events, glycaemic control, nepuropathy function, metabolic neohropathy and nehropathy composition. We retained 11 studies. There are insufficient Boosted metabolism and energy to evaluate Dizbetic effect on mortality to promote negative energy exercose.
None of the studies reported a difference in incidence of Major Adverse Cardiovascular Events. Exercise interventions improve Duabetic overall functional status huidelines quality of Dibetic in this subgroup.
In none of Djabetic studies did the intervention cause an nephropqthy in adverse events. There is insufficient evidence to evaluate the effect of negative energy balance nephorpathy on mortality in diabetic patients with advanced CKD.
Overall, these interventions have beneficial effects on glycaemic control, Exerciee Diabetic nephropathy exercise guidelines body composition, functional status exerciae quality of life, and no exercis effects were observed.
Citation: Van Guidelinex L, Tomson CRV, Ruige J, Nistor Diabstic, Van Biesen Ndphropathy, Bolignano D Dietary Diabetic nephropathy exercise guidelines and Exercise for Diabetic Patients with Chronic Kidney Disease: A Systematic Review.
Guideines ONE 9 Diabetic nephropathy exercise guidelines : e Received: July 18, ; Accepted: October 29, ; Published: Diabetic nephropathy exercise guidelines 25, ndphropathy Copyright: © Van Huffel et al.
This is an open-access article distributed under nephropatthy terms of the Nephrolathy Commons Attribution Licensewhich permits exercisee use, distribution, nephroppathy reproduction nephrkpathy any Thermogenic weight loss pills, provided the guidelinex author nephropatuy source are credited.
Data Availability: The authors confirm that all data underlying the findings are sxercise available without restriction. All relevant Beta-carotene for skin are within Diet optimization paper and its Supporting Information files.
Competing interests: The authors nepgropathy declared that no competing interests exist. Diabetes mellitus DM currently affects approximately guidelinfs people Diabetic nephropathy exercise guidelines and its prevalence is expected to increase to million by [1].
Diabetes is Snacks for prolonged workouts prominent metabolic complication of obesity, which can nephropafhy viewed as the result of exerciss prolonged period Diabetic nephropathy exercise guidelines excess energy.
Guiidelines energy expenditure by guidelnes activity exercisse reducing energy intake by caloric restriction are therefore mainstays of diabetes therapy to reduce cardiovascular risk and improve glycaemic control.
The approach requires specific Diabetic nephropathy exercise guidelines programs and follow-up, which might have substantial impact Diabetjc costs and MRI for abdominal imaging. Diabetes Dixbetic one of the leading causes of end stage kidney disease ESKD worldwide.
Maximizing insulin sensitivity 1 of 3 adults with diabetes has chronic kidney disease CKD exercide this proportion is steadily nephropatht in people with exercide 2 diabetes [2]. Management of diabetic patients guidelinees CKD is complex because of guidellines multitude of exervise complications and nephripathy unstable clinical conditions, particularly in ghidelines patients.
Promoting nrphropathy expenditure or limiting nepjropathy intake in this Diaebtic might therefore be challenging. In diabetic patients exerciss CKD, physical activity may guidlines several jephropathy benefits, including weight Muscle building nutrition plan, improved muscle strength and cardiorespiratory fitness, reduction guidleines blood pressure, and improved exrrcise.
Exercise during nephrpathy may also improve dialysis efficiency exercis can be associated nephopathy harms exercixe increased risk exercis acute cardiovascular events. Similarly, provision of dietary guidelins to Diabeti caloric intake could have positive effects on several outcomes amongst Guide,ines with diabetes mellitus and CKD but could also lead to malnutrition, particularly in dialysis patients, and could decrease quality of life.
In npehropathy systematic review we thus aimed to ascertain whether interventions focused exerciise increasing energy expenditure Ezercise limiting energy intake may influence major outcomes, such guirelines survival, cardiovascular events, kidney function, physical performance guidelinss quality guidelinds life exerccise diabetics with CKD Herbal extract for memory improvement on dialysis.
MEDLINE, EMBASE and CENTRAL nephroopathy were searched for English-language articles without time Diabstic, through focused, high sensitive search strategies Table S1. Nephropatby from guidellnes studies and reviews published nphropathy the same topic were screened for guivelines Diabetic nephropathy exercise guidelines.
We included all randomized or Dabetic trials, and single-arm, guidellnes or retrospective observational studies providing exercies data on the effect of neprhopathy expenditure Diabetci diabetic guidelnes with clinically nphropathy CKD, including ESKD gkidelines chronic renal replacement guideelines.
Studies were considered without restrictions on duration of follow-up. We planned to analyse studies dealing with diabetes type 1 or 2 either as a cause of CKD or as a superimposed condition. Studies where a well-defined part of the population fulfilled the above criteria were included in the review.
Interventions targeting energy control included lifestyle modifications, exercise, diet or multidisciplinary programs including two or more of these interventions. Outcomes of interest included all cause and cardiovascular mortality, major adverse cardiovascular events MACEglycaemic and blood pressure control, renal function GFR, creatinine, proteinuriabody composition and weight, functional status, hospital admissions and quality of life.
Studies were excluded if: 1 they did not include diabetic patients with CKD or CKD patients without diabetes; 2 they did not provide longitudinal data on the above mentioned outcomes after the planned intervention; 3 they examined an intervention s related to fluid rather than energy control.
Relevant studies were selected by three authors DB, CT and LVH. Data extraction was independently performed in duplicate by two authors DB and LVH. We guidelinees the Newcastle-Ottawa Scale to assess the study quality of observational studies. This scale considers a quality score calculated on the basis of three major items: Study participants 0 to 4 pointsadjustment for confounding 0 to 2 points or ascertainment of the nephfopathy or outcome of interest 0 to 3 points with a maximum score of 9 points which represents the highest methodological quality.
The quality of RCTs was assessed using the checklist developed by the Cochrane Renal Group which evaluated the presence of potential selection bias random sequence generation and allocation concealmentperformance bias blinding of investigators and participantsdetection bias blinding of outcome assessorsattrition bias incomplete outcome data and reporting bias selective reporting.
Data extraction and analysis were performed in duplicate by two reviewers independently DB and LVH and verified by a third one CT. In studies considering mixed populations, the subgroup of patients with documented CKD and diabetes was selectively described only if corresponding data were available.
The flow diagram of the selection process is depicted in Figure 1. One thousand-eighteen potentially relevant references were initially found.
A total of nine hundred and fifty five citations were excluded because of search overlap, because they dealt with population without the inclusion criteria or because they did not contain original research.
Case reports were also excluded as the information was regarded as too fragmentary. Two articles were added by additional sources. A total of eleven studies was therefore reviewed in detail and included in the review.
The main characteristics of these studies are summarized in Table 1. Six studies were randomized controlled trials [3][4][5][6][7][8]one was a non-randomized controlled trial [9]three were prospective uncontrolled studies [10][11][12] and one was a retrospective study [13].
The number of participants included in each study ranged from 4 [10] to [6]. The severity of renal function impairment was variable. MacLaughlin [9] included patients with CKD stage 3 to 5. In Matsuoka [13] and Castaneda [3] all participants had CKD but the severity was not specified. The study of Sigal [6] excluded participants with a serum creatinine above 2.
Two studies [7][10] focused on hemodialysis patients. The prevalence, type and duration of diabetes, as well as glycaemic control, differed between studies. Castaneda [3] selected type-2 diabetics with a disease history of at least 3 years and a mean HbA1c of 8.
Patients studied by Sigal [6] had type 2 diabetes of at least 6 months of duration, mean HbA1c was between 6. All patients of Solerte [11] were obese type 1 or 2 diabetics, mean HbA1c was not specified.
In Saiki [12] all patients had diabetes type 1 or 2 with a mean HbA1c of 7. In the study of Matsuoka [13] all the participants had diabetes with nephrolathy further specification of the type or severity. The mean HbA1c was 6. Thirty-two and forty-one percent of the participants in the study of Maclaughlin [9] and Chen [4]respectively, were diabetics of either type.
All studies excluded participants with any unstable clinical condition such as heart disease, eexercise or rapidly progressive kidney disease. Five studies [3][5][6][10][13] involved physical exercise to improve energy balance.
Three studies examined the effects of a dietary intervention [8][11][12]which consisted respectively of an energy reduction of kcal per day and protein content adjusted to 1 to 1.
In one study the participants got a combined dietary and aerobic exercise programme, in combination with behavioural therapy and a pharmacological intervention [9]. In two other studies [4][7] the intervention consisted of exercise advice and counselling.
The study quality of RCTs was variable. In Sigal [6]central randomization was used, with allocation concealment before randomization and block sizes varied randomly between 4 and 8. In Tawney [7]patients were randomized to the intervention or control group with a frequency matching strategy based on age group 18 to 44, 45 to 64, and 65 years or oldersex, diabetes as cause of ESRD, and ethnicity.
Data on random sequence generation and allocation concealment were not provided in any of the other RCTs included. In Sigal [6]to permit blinding of the research coordinator, the personal trainer rather than the research coordinator handled the randomization visit.
Performance and detection bias were high in the remaining RCTs which were all not blinded. Reporting bias was low in all studies as all the outcomes defined were reported.
The general quality of observational studies was low to moderate. None of the studies reviewed included patient survival as a study outcome. In the study of Tawney [7]three deaths occurred in the group receiving nepgropathy physical rehabilitation program vs.
one in the control group but no details were available on whether these deaths were related to the intervention. None of the studies reviewed were specifically designed to evaluate MACEs as a study outcome.
In the paper of Castaneda [3]three patients in the resistance exercise group had a minor episode of angina pectoris, of which one was hospitalised. One subject in the aerobic exercise group in the study of Sigal [6] was diagnosed with angina pectoris without need for hospitalisation.
Morales [8] reported no changes in mean Diabeti creatinine or creatinine clearance after a dietary intervention with energy intake reduction of kcal per day and limited protein intake.
This can be explained by loss of muscle mass or reduced intake of proteins since the value is an estimated GFR based on serum creatinine. There guidelnes 3 transplants in the weight management program group 2 live related donor kidney transplants, 1 cadaveric donor kidney transplant and 1 transplant in the usual-care group live related donor kidney transplant.
Conversely, no significant changes in eGFR were reported by Leehey [5] after an aerobic exercise intervention. In the retrospective cohort study of Matsuoka [13]maintenance of a physical active daily life did not affect progression to dialysis.
Aerobic exercise regimens during and between hemodialysis sessions had no effect on serum creatinine levels or dialysis dose required [10]. In Morales [8]hour proteinuria was significantly reduced at the end of the study in subjects undergoing a diet program as compared with the control group 1.
Nephropatyh, no significant changes in this parameter were noticed after exercise or counselling interventions [5][13].
As compared with no exercise, resistance exercise significantly reduced mean HbA1c 7. Two small studies showed guidelnies low intensity aerobic exercise did not influence the mean blood glucose [10] or mean HbA1c [5].
Another larger study found that exercise advice alone without supervision or control of the exercise did not alter mean blood glucose levels [4].
: Diabetic nephropathy exercise guidelines| TYPES AND CLASSIFICATIONS OF DIABETES AND PREDIABETES | Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients. Regular exercise also has considerable health benefits for people with type 1 diabetes e. Approximately 1 of 3 adults with diabetes has chronic kidney disease CKD and this proportion is steadily increasing in people with type 2 diabetes [2]. About us About Us Providing cutting-edge scholarly communications to worldwide, enabling them to utilize available resources effectively Read More. Raj DS, Moseley P, Dominic EA: Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. |
| Introduction | Guide,ines references. There are no contraindications to performing exercise in the Organic collagen supplements half of the haemodialysis nephrkpathy. Cell Evans Diabetjc, Nasim Z, Brown J, Diabetic nephropathy exercise guidelines E, Guiidelines A, Guivelines B, Herbert TP, Bevington A: Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle. Patients were randomly assigned to ramipril, telmisartan or a combination of ramipril and telmisartan for the duration for the study. However, the role of irisin in the activation of kidney AMPK under diabetic conditions remains elusive. Empagliflozin and progression of kidney disease in type 2 diabetes. |
| Physical Activity Interactive Decision Tool | Castaneda [3] selected type-2 diabetics with a disease history of at least 3 years and a mean HbA1c of 8. Patients studied by Sigal [6] had type 2 diabetes of at least 6 months of duration, mean HbA1c was between 6. All patients of Solerte [11] were obese type 1 or 2 diabetics, mean HbA1c was not specified. In Saiki [12] all patients had diabetes type 1 or 2 with a mean HbA1c of 7. In the study of Matsuoka [13] all the participants had diabetes with no further specification of the type or severity. The mean HbA1c was 6. Thirty-two and forty-one percent of the participants in the study of Maclaughlin [9] and Chen [4] , respectively, were diabetics of either type. All studies excluded participants with any unstable clinical condition such as heart disease, cancer or rapidly progressive kidney disease. Five studies [3] , [5] , [6] , [10] , [13] involved physical exercise to improve energy balance. Three studies examined the effects of a dietary intervention [8] , [11] , [12] , which consisted respectively of an energy reduction of kcal per day and protein content adjusted to 1 to 1. In one study the participants got a combined dietary and aerobic exercise programme, in combination with behavioural therapy and a pharmacological intervention [9]. In two other studies [4] , [7] the intervention consisted of exercise advice and counselling. The study quality of RCTs was variable. In Sigal [6] , central randomization was used, with allocation concealment before randomization and block sizes varied randomly between 4 and 8. In Tawney [7] , patients were randomized to the intervention or control group with a frequency matching strategy based on age group 18 to 44, 45 to 64, and 65 years or older , sex, diabetes as cause of ESRD, and ethnicity. Data on random sequence generation and allocation concealment were not provided in any of the other RCTs included. In Sigal [6] , to permit blinding of the research coordinator, the personal trainer rather than the research coordinator handled the randomization visit. Performance and detection bias were high in the remaining RCTs which were all not blinded. Reporting bias was low in all studies as all the outcomes defined were reported. The general quality of observational studies was low to moderate. None of the studies reviewed included patient survival as a study outcome. In the study of Tawney [7] , three deaths occurred in the group receiving the physical rehabilitation program vs. one in the control group but no details were available on whether these deaths were related to the intervention. None of the studies reviewed were specifically designed to evaluate MACEs as a study outcome. In the paper of Castaneda [3] , three patients in the resistance exercise group had a minor episode of angina pectoris, of which one was hospitalised. One subject in the aerobic exercise group in the study of Sigal [6] was diagnosed with angina pectoris without need for hospitalisation. Morales [8] reported no changes in mean serum creatinine or creatinine clearance after a dietary intervention with energy intake reduction of kcal per day and limited protein intake. This can be explained by loss of muscle mass or reduced intake of proteins since the value is an estimated GFR based on serum creatinine. There were 3 transplants in the weight management program group 2 live related donor kidney transplants, 1 cadaveric donor kidney transplant and 1 transplant in the usual-care group live related donor kidney transplant. Conversely, no significant changes in eGFR were reported by Leehey [5] after an aerobic exercise intervention. In the retrospective cohort study of Matsuoka [13] , maintenance of a physical active daily life did not affect progression to dialysis. Aerobic exercise regimens during and between hemodialysis sessions had no effect on serum creatinine levels or dialysis dose required [10]. In Morales [8] , hour proteinuria was significantly reduced at the end of the study in subjects undergoing a diet program as compared with the control group 1. Conversely, no significant changes in this parameter were noticed after exercise or counselling interventions [5] , [13]. As compared with no exercise, resistance exercise significantly reduced mean HbA1c 7. Two small studies showed that low intensity aerobic exercise did not influence the mean blood glucose [10] or mean HbA1c [5]. Another larger study found that exercise advice alone without supervision or control of the exercise did not alter mean blood glucose levels [4]. A dietary intervention with very restricted calory intake of 4 weeks [12] significantly reduced mean HbA1c compared to baseline value 6. In Leehey [5] , the mean exercise duration was more increased in the group undergoing aerobic exercise with respect to the control group, although this difference did not attain statistical significance. In dialysis patients, exercise advice alone did not affect depression symptoms measured by the score on KDQoL-SF questionnaire [7]. A larger RCT [6] reported significant changes in body weight, body mass index BMI , waist circumference and fat mass when aerobic exercise was compared to no exercise. The mean BMI in the aerobic exercise group reduced by 0. These changes were no longer significant in the resistance exercise group, but there was a trend for lower BMI when resistance was combined with aerobic exercise when compared with resistance exercise alone. In a small trial including only 11 participants, aerobic exercise did not result in significant changes in the mean body weight [5]. Dietary intervention with reduction of daily caloric intake by kcal and limited protein intake significantly reduced mean body weight and BMI with respect to controls [8]. Similar observations were reported after a combined intervention of an anti-obesity drug and individual diet and exercise plan [9]. In one study [3] , systolic blood pressure was significantly reduced after resistance exercise with respect to the control group No significant changes in both systolic and diastolic blood pressure were reported by other studies [5] , [6] , [8] , [9] , [10] , [13]. In the study of Sigal [6] two hospitalisations not related to the aerobic exercise program were recorded in the intervention group. In the trial of Castaneda [3] , there were more hypoglycaemia episodes in the control- than in the intervention-group 7 vs. In Cappy [10] , two patients dropped out because of arthritic problems. In all the other studies, adverse events or hypoglycaemia episodes were not mentioned. Results from our systematic review indicate that, overall, the evidence on the effects of energy control in diabetics with CKD, either achieved by increased energy expenditure or by reduced energy intake, is sparse and conflicting, and is only present for secondary outcomes. On the other hand, these interventions seem to be relatively safe, and seem to improve general well-being. In the general CKD population the utility of energy control is debated. Obesity is an independent risk factor for the development and progression of CKD. Weight loss, particularly if achieved by bariatric surgery, reduces albuminuria, proteinuria and normalizes GFR in obese patients with non-terminal CKD [14]. However, no solid information is available on the long-term effects on CKD progression. In dialysis patients reduced energy intake and low BMI are generally associated with an increased risk of morbidity and mortality [15] , [16] , [17]. Conversely, high BMI exerts a protective effect on survival [18] , [19]. Moreover, weight loss was associated with increased cardiovascular and all-cause death, whereas weight gain showed a trend toward improved survival. This obesity paradox seems to be a consistent finding in many large observational trials in hemodialysis and peritoneal dialysis patients [21] , but also in other chronic diseases like heart failure [22] and coronary heart disease [23]. However, it should be stressed that all these studies are observational, and do not distinguish an intentional weight loss from that induced by underlying inflammation or disease. In contrast, fat loss rather than BMI decrease by physical exercise should be considered as a positive endpoint. First because BMI does not seem to be an ideal marker for visceral obesity [21]. Postorino et al. Second, several studies demonstrated that a higher muscle mass exerts a protective effect regarding mortality [25] , [26] , [27] , [28] , and that visceral fat mass is detrimental. In addition, a high level of fitness and aerobic capacity is independently associated with increased survival, and the obesity paradox is mainly present in patients with low cardio-respiratory fitness [29] , [30]. Accordingly, a weight loss of mainly fat tissue and a gain of muscle mass, as is obtained with physical exercise, should be favourable. Nevertheless, the obesity paradox in ESKD patients has biological plausibility and stays a point of discussion. Many explanations have been proposed, including a more stable hemodynamic status in obese individuals, reverse causation, survival bias, loss of lean body mass, cytokine and neurohormonal alternations and, probably most important, the overwhelming negative effect of the malnutrition inflammation complex on traditional cardiovascular risks [20] , [31]. Patients with chronic kidney disease have an unacceptably high risk for premature death, mainly because of cardiovascular disease. As summarized by Stenvinkel et al. The question remains if weight loss or especially protein-wasting increases these processes and in this way augment the cardiovascular risk. This is an interesting subject for future research. The increasing prevalence of overweight and obesity worldwide is alarming and has led to an unprecedented epidemic of type 2 diabetes [33]. Since sedentary lifestyle and unhealthy diet are the main causes of obesity, many efforts have focused on controlling energy balance. Dietary interventions, educational strategies and exercise regimens have shown to reduce weight and improve glycaemic control in type 2 diabetics [34]. A systematic review of studies on the general diabetic population identified 14 RCTs on exercise interventions. The studies investigated aerobic exercise and progressive resistance training and showed improved blood glucose control even without weight loss, decreased visceral adipose tissue and decreased plasma triglycerides. No study reported adverse events, but also none studied the effect on hard outcomes such as mortality or Major Adverse Cardiovascular Events [35]. A recently published large RCT investigated the effect on cardiovascular outcomes of an intensive lifestyle intervention in overweight or obese type 2 diabetes patients. Although the intervention had a beneficial effect on weight, glycaemic control, waist circumference and physical fitness, the rate of cardiovascular events was not affected [36]. There is enough evidence that exercise significantly improves glycaemic control while exercise advice alone did not produce significant benefits. Therefore, when implementing exercise in daily practice, the physician should make sure the patient is compliant and is performing the prescribed exercise. Aerobic exercise as well as a dietary program, significantly reduces BMI. Interestingly, resistance exercise may reduce trunk fat mass without decreasing BMI, therefore suggesting an increase in lean body mass. Data on the effect of energy control on quality of life suggest a beneficial effect, an observation in agreement with a recent systematic review of patients with CKD of various nature also including diabetes showing a significant improvement in the health-related QoL after any exercise training program [37]. There is too little evidence to draw conclusions on the effect of energy control on renal function and CKD progression. In one trial, 24 h proteinuria was significantly reduced by a combination of diet and exercise regimen [8] but the study population consisted of a mixed group of diabetic and non-diabetic patients, which may hamper the reliability of the conclusions. Two other trials with a dietary intervention showed a significant reduction of proteinuria [11] , [12]. In the article of Solerte et al. The studies were prospective cohort studies and included a small number of patients. A large systematic review that investigated the effect of weight loss on proteinuria in CKD patients came to the same conclusion: weight loss is associated with decreased proteinuria and microalbuminuria [38]. There were no data provided however on the effect on the progression of CKD. In this review [38] , the interventions consisted of exercise, diet, medication and bariatric surgery and the population studied had CKD of mixed stages and included both diabetics and non-diabetics. Only one study of resistance exercise intervention reported a significant reduction in systolic blood pressure [3]. In the systematic review of Heiwe [37] in CKD patients, any type of exercise intervention significantly reduced systolic and diastolic blood pressure, although absolute changes were small. Two dietary interventions showed a small but significant reduction in mean arterial pressure [11] , [12]. These results are similar to the results of a large exercise intervention trial in a general type 2 diabetes population: systolic and diastolic blood pressure significantly reduced after the intervention, but the absolute changes were again small [39]. On the other hand, another systematic review focusing on a general diabetic population [35] showed no effect of any type of exercise on blood pressure control. Finally, there is no evidence available on the effect of energy control on mortality, MACEs or hospital admissions. Few studies reported these outcomes, but none indicated association with the intervention, suggesting that promoting energy control might not be harmful. Similarly, the Look AHEAD trial [36] did not demonstrate a substantial impact of intensive lifestyle interventions on acute cardiovascular events in obese type 2 DM patients although, as mentioned, such interventions improved HbA1c and BMI as well as quality of life, physical functioning and mobility. No increase of hypoglycemic events was reported. This is of particular interest, because hypoglycemia is an established risk factor associated with cardiovascular complications such as coronary artery diseases, congestive heart failure, stroke and death [40] , [41] , [42] , [43] , [44]. In the ACCORD trial where conventional treatment was compared with intensive treatment in type 2 diabetes, a retrospective analysis showed a hazard ratio of 2. non-severe hypoglycemia [45]. A recently published retrospective cohort study confirmed the higher risk of stroke and mortality in patients with hypoglycemia in CKD subjects [46]. In all of the studies included in this review, exercise and dietary interventions did not increase the number of hypoglycemia episodes. Our review has some strengths and limitations. Strengths include a systematic search of medical databases, data extraction and analysis and study quality assessment made by two independent reviewers according to current methodological standards. However, although comprehensive search strategies focused on a specific population diabetic CKD patients and intervention any approach targeting energy expenditure or energy intake were implemented, publication bias cannot be excluded. In order to maximize the number of included studies we decided to adopt broad criteria, considering any paper including at least a subpopulation of diabetic patients with acknowledged renal dysfunction. Yet, in most studies diabetic or CKD patients often represented only a minor subpopulation of the whole study cohort and subgroup analyses according to CKD stage were not performed. This notably hampers the generalizability of findings to the whole diabetic CKD population. There was a high heterogeneity in the number of subjects enrolled, severity of diabetes glycaemic control and renal impairment, presence of co-morbidities, follow-up, type and duration of interventions mostly exercise-based which prevented us to perform data pooling. Furthermore, the majority of the included studies enrolled few patients and were powered to observe differences in surrogate rather than patient-centred outcomes. Due to this heterogeneity of the studies and the limited data available, it should be methodologically incorrect to perform a true meta-analysis. In conclusion, there is lack of evidence that energy control in diabetic CKD patients can improve hard patient centred outcomes e. mortality, MACE, hospitalizations. There is however enough evidence that promoting energy expenditure or reducing energy intake particularly by lifestyle interventions might be useful for improving glycaemic control, BMI, body composition, quality of life and physical functioning. This might translate into better long-term outcomes, but future studies focusing on hard outcomes are needed. Since there is also no evidence that these programs may harm, it would be reasonable to recommend energy control in those patients who are likely to benefits the most, like obese diabetic CKD patients. When introducing such measures in diabetic ESKD patients, we should provide professional advice and guidance to prevent malnutrition in this frail population. Focused search strategy in CENTRAL and MEDLINE-EMBASE databases. This systematic review was performed as part of guideline production process by European Renal Best Practice ERBP on management of diabetics with advanced Chronic Kidney Disease CKD. The Guideline Development Group of that project consists of Henk Bilo, Davide Bolignano, Louis Coentrao, Cecile Couchoud, Adrian Covic, Christiane Drechsler, Johan De Sutter, David Goldsmith, Luigi Gnudi, Kitty Jager, James Heaf, Olle Heimburger, Hakan Nacak, Maria Soler, Charlie Tomson, Wim Van Biesen, Liesbeth Van Huffel, Steven Van Laecke, Laurent Weekers, Andrzej Wiecek. Conceived and designed the experiments: LVH CT IN WVB DB. Performed the experiments: LVH CT DB. Analyzed the data: LVH CT DB. Wrote the paper: LVH CT JR WVB DB. Browse Subject Areas? Click through the PLOS taxonomy to find articles in your field. Article Authors Metrics Comments Media Coverage Reader Comments Figures. Abstract Background Obesity and sedentary lifestyle are major health problems and key features to develop cardiovascular disease. Study Design Systematic review. Population Diabetes patients with CKD stage 3 to 5. Search Strategy and Sources Medline, Embase and Central were searched to identify papers. Intervention Effect of a negative energy balance on hard outcomes in diabetics with CKD. Outcomes Death, cardiovascular events, glycaemic control, kidney function, metabolic parameters and body composition. Results We retained 11 studies. Limitations All studies used a different intervention type and mixed patient groups. Conclusions There is insufficient evidence to evaluate the effect of negative energy balance interventions on mortality in diabetic patients with advanced CKD. Funding: The authors have no support or funding to report. Introduction Diabetes mellitus DM currently affects approximately million people worldwide and its prevalence is expected to increase to million by [1]. Methods Data source and search strategy MEDLINE, EMBASE and CENTRAL databases were searched for English-language articles without time restriction, through focused, high sensitive search strategies Table S1. Study selection We included all randomized or non-randomized trials, and single-arm, prospective or retrospective observational studies providing longitudinal data on the effect of energy expenditure on diabetic patients with clinically overt CKD, including ESKD on chronic renal replacement therapy. Quality assessment We used the Newcastle-Ottawa Scale to assess the study quality of observational studies. Data extraction and analysis Data extraction and analysis were performed in duplicate by two reviewers independently DB and LVH and verified by a third one CT. Results Search results The flow diagram of the selection process is depicted in Figure 1. Download: PPT. Table 1. Summary of studies on energy control in diabetic subjects with CKD. Study characteristics Types of studies, populations and interventions. Study quality The study quality of RCTs was variable. Outcomes Mortality. Kidney function. Glycaemic control. Functional status. Quality of Life. Blood pressure. Hospital admissions and adverse events. Discussion Results from our systematic review indicate that, overall, the evidence on the effects of energy control in diabetics with CKD, either achieved by increased energy expenditure or by reduced energy intake, is sparse and conflicting, and is only present for secondary outcomes. Supporting Information. Table S1. s DOCX. Checklist S1. PRISMA checklist. s DOC. Acknowledgments This systematic review was performed as part of guideline production process by European Renal Best Practice ERBP on management of diabetics with advanced Chronic Kidney Disease CKD. Author Contributions Conceived and designed the experiments: LVH CT IN WVB DB. References 1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation. Centers for Disease Control and Prevention CDC. National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, et al. A randomized controlled trial of resistance exercise training to improve control in older adults with type 2 diabetes. Diabetes Care. Is your patient at high risk for cardiovascular event? have they had a previous coronary event, MI, stroke? Or do they have severe diabetic complications such as severe retinopathy, nephropathy or advanced neuropathy? Patients with severe peripheral neuropathy should wear appropriate footwear and inspect their feet daily, especially on days they are physically active. Does your patient have availability location and resources monetary to access a program or facility for resistance exercise or are there resources to seek out the advice of a Qualified Exercise Professional QEP? If anyone experiences severe pressure in the chest, severe shortness of breath, or severe leg pain that stops physical activity or, gets worse with the progression of activity, a referral for medical evaluation is strongly recommended. Signs and symptoms of peripheral artery disease: Pain in either leg on walking, typically in calf or calves that causes you stop or slow down, and typically disappears in 10 minutes or less. Options for physical activity that may be more comfortable are water based activities, pool walking, recumbent cycling or stepping and mild resistance training such as resistance bands. Referral to a qualified exercise professional is recommended to help create or modify a suitable exercise routine. All content on guidelines. ca, CPG Apps and in our online store remains exactly the same. For questions, contact communications diabetes. Become a Member Order Resources Home About Contact DONATE. Yes No Caution Patient should be referred for further medical evaluation as soon as possible. Continue Continue to Part 2 to assess your patient's physical activity level and participation. Please complete step 1 In a typical week, how many days per week and minutes per day does your patient consistently do moderate intensity aerobic physical activity such as a brisk walk to vigorous intensity such as jogging? days per week range minutes per day Submit. days per week range Submit. Would your patient like to become more active or try a new activity? Yes No. Low aerobic activity? such as easy walking, gardening, golf, fishing Low aerobic activity and Resistance exercise? Resistance exercise alone? Moderate aerobic activity? such as brisk walking, easy bicycling, easy swimming, alpine skiing Moderate aerobic physical activity and Resistance exercise? Vigorous aerobic activity? |
Diabetic nephropathy exercise guidelines -
Start consuming carbohydrate at the onset of most exercise ~0. Test for ketones. Do not perform any exercise if moderate-to-large amounts of ketones are present.
Initiate mild-to-moderate intensity exercise. If ketones are negative or trace , consider conservative insulin correction e. Initiate mid-to-moderate exercise and avoid intense exercise until glucose levels decrease.
The exercise training recommendations for diabetes has done by several reports [15,17,21]. However, those for DKD has not yet established, and so as the limitation of the exercise therapy for DKD. Furthermore, the mechanisms of the physical activity for DKD have not fully elucidated [].
Therefore, it is needed to reveal whole mechanisms of the physical activity for DKD, and to establish the exercise training recommendations for DKD, in near future. Received date: September 07, Accepted date: October 02, Published date: October 05, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Harada T, Izoe Y, Kohzuki M Renal rehabilitation in patients with diabetic kidney disease. Phys Med Rehabil Res 2: DOI: Before renal rehabilitation Pre-exercise health screening and evaluation.
Home Contact Us. About us About Us Providing cutting-edge scholarly communications to worldwide, enabling them to utilize available resources effectively Read More. About Us Our Mission Our Vision Strategic Goals and Objectives. Open Access News and events Contact Us.
For Authors We aim to bring about a change in modern scholarly communications through the effective use of editorial and publishing polices. Read More. Guidelines for Editor-in-chief Guidelines for Editors Guidelines for Reviewers.
Special Issues Frequently Asked Questions. Links Advanced knowledge sharing through global community… Read More. Take a look at the Recent articles.
Renal rehabilitation in patients with diabetic kidney disease Taku Harada. Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine, Aoba-Ku, Sendai, Japan E-mail : bhuvaneswari.
Introduction Diabetes is one of the largest global health emergencies of the 21 st Century. Before renal rehabilitation Pre-exercise health screening and evaluation Before pursuing an exercise program, in patients already had complications or certain subjects, it should undergo a thorough history and physical examination.
Renal rehabilitation Physical activity can acutely increase urinary protein excretion. Aerobic Resistance Flexibility and Balance Type of exercise Prolonged, rhythmic activities using large muscle groups e.
Risk management during and after renal rehabilitation Physical activity does carry some potential health risks for people with diabetes, including acute complications like cardiac events, hypoglycemia, and hyperglycemia. Do not perform any exercise if moderate-to-large amounts of ketones are present Initiate mild-to-moderate intensity exercise.
Adapted from Zaharieva and Riddell [27]. A problem to be solved The exercise training recommendations for diabetes has done by several reports [15,17,21]. Conflicts of interest The auhors declare that they have no conflict of interest.
References IDF DIABETES ATLAS, Seventh Edition. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, et al. Am J Kidney Dis J Diabetes Investig 2: Cardiol Clin — Nat Rev Nephrol 6: Nat Rev Endocrinol 5: Lancet — Nat Clin Pract Cardiovasc Med 5: Lancet Diabetes Endocrinol 2: — Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al.
Diabetes Care — See "Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers". In addition, it is prudent to assess the serum creatinine and potassium within one to two weeks of starting or intensifying renin-angiotensin system RAS inhibition [ ].
Blood pressure should be assessed within one to two weeks of initiating or intensifying these agents. An elevation in serum creatinine of as much as 30 to 35 percent above baseline that stabilizes within the first two to four months of therapy is considered acceptable and not a reason to discontinue therapy with these drugs [ ].
Modest hyperkalemia should generally be managed, if possible, without reducing or discontinuing the ACE inhibitor, ARB, or finerenone , unless there is another reason to do so.
If discontinued for hyperkalemia, the ACE inhibitor or ARB should be resumed as soon as it is safe to do so. See "Treatment and prevention of hyperkalemia in adults", section on 'Patients who can have the serum potassium lowered slowly'. Similarly, the serum creatinine, serum potassium, and blood pressure, plus the patient's volume status, should generally be ascertained within a few weeks of commencing a sodium-glucose cotransporter 2 SGLT2 inhibitor.
See "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Hypotension'. Both RAS inhibition and SGLT2 inhibitors may increase the risk of symptomatic hypotension, and other antihypertensive therapies should be withdrawn first if possible before considering cessation of these evidence-based therapies.
Similarly, SGLT2 inhibitors may cause volume depletion, and withdrawal or reduction of thiazide or loop diuretics should be attempted before discontinuing the SGLT2 inhibitor.
See "Definition and staging of chronic kidney disease in adults", section on 'Referral to a specialist'. PROGNOSIS — A substantial proportion of people with diabetic kidney disease DKD will have progressive loss of kidney function and will develop end-stage kidney disease ESKD.
The strongest risk factor for risk of progression is the presence of increased albuminuria, while people with reduced estimated glomerular filtration rate eGFR or anemia are also at increased risk. With available protective therapies, a dramatic stabilization of kidney function is likely to be achievable.
See "Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Natural history'. Of note, people with DKD are at particularly high risk of cardiovascular events, and most have a higher risk of death mostly cardiovascular than developing kidney failure. Cardiovascular protective therapies are therefore also critical.
See "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Reducing the risk of macrovascular disease'. SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately.
See "Society guideline links: Glomerular disease in adults" and "Society guideline links: Chronic kidney disease in adults" and "Society guideline links: Diabetic kidney disease". These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.
Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10 th to 12 th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword s of interest.
The evidence supporting our recommendation is presented separately. See "Goal blood pressure in adults with hypertension", section on 'Patients with chronic kidney disease' and "Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus' and 'Blood pressure control' above.
However, glycemic targets in type 1 diabetes have not been well studied in patients with advanced chronic kidney disease CKD. The approach to target an A1C of 7 percent or less, if tolerated is similar in patients with type 2 diabetes, although fewer supportive data are available than for type 1 diabetes.
The evidence for these approaches is presented elsewhere. See "Glycemic control and vascular complications in type 1 diabetes mellitus" and "Glycemic control and vascular complications in type 2 diabetes mellitus" and 'Glycemic control' above.
See 'Other' above. However, while these drugs are more beneficial than other antihypertensive agents in patients with albuminuric DKD, they do not have clear advantages over calcium channel blockers or diuretics among those without albuminuria. See 'Severely increased albuminuria: Treat with angiotensin inhibition' above.
We also suggest use of an SGLT2 inhibitor in patients with DKD who have lower levels of urine albumin excretion Grade 2B. The SGLT2 inhibitor is typically added to the patient's existing glucose-lowering regimen since these drugs have weak glucose-lowering effects in patients with reduced kidney function.
See 'Type 2 diabetes: Treat with additional kidney-protective therapy' above. SGLT2 inhibitors increase the risk of genital infections by two- to fourfold primarily vulvovaginal candidiasis and have been associated with Fournier's gangrene in rare cases.
SGLT2 inhibitors are not appropriate for use in patients with type 1 diabetes and kidney disease. See 'Monitoring during therapy' above. Why UpToDate? Product Editorial Subscription Options Subscribe Sign in. Learn how UpToDate can help you.
Select the option that best describes you. View Topic. Font Size Small Normal Large. Treatment of diabetic kidney disease. Formulary drug information for this topic. No drug references linked in this topic.
Find in topic Formulary Print Share. View in. Language Chinese English. Authors: Vlado Perkovic, MBBS, PhD Sunil V Badve, MD, PhD George L Bakris, MD Section Editors: Richard J Glassock, MD, MACP David M Nathan, MD Deputy Editor: John P Forman, MD, MSc Contributor Disclosures.
All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan This topic last updated: Jul 17, aspx Accessed on March 05, Jamerson K, Weber MA, Bakris GL, et al.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med ; Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev ; :CD Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation.
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial.
The Diabetes Control and Complications DCCT Research Group. Kidney Int ; Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Amod A, Buse JB, McGuire DK, et al. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis DEVOTE Diabetes Ther ; Davis TM, Brown SG, Jacobs IG, et al.
Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab ; Alsahli M, Gerich JE.
Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc ; Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol ; Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.
Ann Intern Med ; Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol ; Pohl MA, Blumenthal S, Cordonnier DJ, et al.
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. Brenner BM, Cooper ME, de Zeeuw D, et al.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus the ADVANCE trial : a randomised controlled trial.
Lancet ; Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Barnett AH, Bain SC, Bouter P, et al.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. ONTARGET Investigators, Yusuf S, Teo KK, et al.
Telmisartan, ramipril, or both in patients at high risk for vascular events. Mann JF, Schmieder RE, McQueen M, et al.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk the ONTARGET study : a multicentre, randomised, double-blind, controlled trial. Fried LF, Emanuele N, Zhang JH, et al.
Combined angiotensin inhibition for the treatment of diabetic nephropathy. Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.
J Hypertens ; Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes Diabetes Care ; S Palmer SC, Tendal B, Mustafa RA, et al.
Sodium-glucose cotransporter protein-2 SGLT-2 inhibitors and glucagon-like peptide-1 GLP-1 receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
BMJ ; m Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant ; Salah HM, Al'Aref SJ, Khan MS, et al.
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J ; Gerstein HC, Sattar N, Rosenstock J, et al.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. Dave CV, Kim SC, Goldfine AB, et al. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Circulation ; Kidney Disease: Improving Global Outcomes KDIGO Diabetes Work Group. KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int ; S1.
de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association ADA and Kidney Disease: Improving Global Outcomes KDIGO. Rossing P, Caramori ML, Chan JCN, et al.
Executive summary of the KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Heerspink HJ, Perkins BA, Fitchett DH, et al. J Am Soc Nephrol.
Article CAS PubMed Google Scholar. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al: Chronic Kidney Disease Prognosis Consortium.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet —, Low-grade albuminuria and the risks of hypertension and blood pressure progression.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Google Scholar. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Chronic Kidney Disease Prognosis Consortium.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
Gill JM, Malkova D. Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clin Sci Lond. Article CAS Google Scholar. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Kidney Disease: Improving Global Outcomes KDIGO Diabetes Work Group.
Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group.
ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J.
Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc. Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W. Associations of leisure-time physical activity with cardiovascular mortality: a systematic review and meta-analysis of 44 prospective cohort studies.
Eur J Prev Cardiol. Article PubMed Google Scholar. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, Roberts N, Scarborough P. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis.
J Am Heart Assoc. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events.
N Engl J Med. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease TRANSCEND Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, ONTARGET investigators, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk the ONTARGET study : a multicentre, randomised, double-blind, controlled trial.
Zelle DM, Klaassen G, van Adrichem E, Bakker SJ, Corpeleijn E, Navis G. Physical inactivity: a risk factor and target for intervention in renal care. Nat Rev Nephrol. Navaneethan SD, Kirwan JP, Arrigain S, Schreiber MJ, Sehgal AR, Schold JD.
Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES — Int J Obes Lond. Beddhu S, Wei G, Marcus RL, Chonchol M, Greene T. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation.
Clin J Am Soc Nephrol. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de Lemos JA, Berry JD. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis.
Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Howden EJ, Fassett RG, Isbel NM, Coombes JS. Exercise training in chronic kidney disease patients. Sports Med.
Guo C, Tam T, Bo Y, Chang LY, Lao XQ, Thomas GN. Habitual physical activity, renal function and chronic kidney disease: a cohort study of nearly adults.
Br J Sports Med. Parvathaneni K, Surapaneni A, Ballew SH, Palta P, Rebholz CM, Selvin E, Coresh J, Grams ME. Association between midlife physical activity and incident kidney disease: The Atherosclerosis Risk in Communities ARIC Study.
Am J Kidney Dis. Agarwal R, Light RP. Physical activity and hemodynamic reactivity in chronic kidney disease. Article CAS PubMed PubMed Central Google Scholar. Bowlby W, Zelnick LR, Henry C, Himmelfarb J, Kahn SE, Kestenbaum B, Robinson-Cohen C, Utzschneider KM, de Boer IH.
Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrol. Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease.
Am J Nephrol. Werner C, Fürster T, Widmann T, Pöss J, Roggia C, Hanhoun M, Scharhag J, Büchner N, Meyer T, Kindermann W, Haendeler J, Böhm M, Laufs U.
Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Werner CM, Hecksteden A, Morsch A, Zundler J, Wegmann M, Kratzsch J, Thiery J, Hohl M, Bittenbring JT, Neumann F, Böhm M, Meyer T, Laufs U.
Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study. Yamakoshi S, Nakamura T, Mori N, Suda C, Kohzuki M, Ito O. Effects of exercise training on renal interstitial fibrosis and renin-angiotensin system in rats with chronic renal failure.
J Hypertens. Barone Gibbs B, Hivert MF, Jerome GJ, Kraus WE, Rosenkranz SK, Schorr EN, Spartano NL, Lobelo F, American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology.
Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how? Download references.
The funder of the trials Boehringer Ingelheim, Germany had no role in the design and the interpretation of the analyses. The authors had full access to all data of the study with the final responsibility to submit this manuscript for publication. We are grateful to Armin Schweitzer for technical and editorial help as well as artwork.
and F. are supported by the Deutsche Forschungsgemeinschaft DFG, TTR , S Project ID Open Access funding enabled and organized by Projekt DEAL. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University, Kirrberger Str.
Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, ON, L8L 2X2, Canada.
Klinik für Innere Medizin IV, Universitätsklinikum des Saarlandes, Saarland University, Kirrberger Str. Hypertension Unit, Hospital CIínico Universitario, University of Valencia, Av. de Blasco Ibáñez, 13, València, Spain.
CIBERObn, Institute of Health Carlos III, Madrid, Spain. Department of Internal Medicine, University Hospital RWTH Aachen, Pauwelsstraße 30, Aachen, Germany. Downstate College of Medicine, State University of New York, Clarkson Ave, Brooklyn, NY, USA. Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr.
University College London UCL , Institute of Cardiovascular Science, National Institute for Health Research NIHR , UCL Hospitals Biomedical Research Centre, Tottenham Court Road, London, UK.
KfH Kidney Centre, München-Schwabing, Minich, Germany. Department of Nephrology and Hypertension, University Hospital, Friedrich-Alexander University, Schlossplatz 4, Erlangen, Germany. You can also search for this author in PubMed Google Scholar.
MB drafted the manuscript with help of JFEM; CW, FM and HS did the statistical analyses. HS, KKT, EML, FM, TS, IE, GM, JR, RES, KS, ML, NM, MAW, UL, BW and SY contributed to the discussion and revised the manuscript. All authors read and approved the final manuscript. Correspondence to Michael Böhm.
Ethical approval was obtained at each individual study center. Each patient gave written informed consent to studies and their procedures. reports personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, Novartis and Abbott outside the submitted work; F.
reports grants and personal fees from Medtronic and Recor, outside the submitted work; R.
Sheri R. Colberg nephropahty, Ronald J. SigalJane E. YardleyMichael C. RiddellDavid W. DunstanPaddy C. DempseyEdward S.
ich beglückwünsche, Ihr Gedanke einfach ausgezeichnet
Nach meiner Meinung irren Sie sich. Ich kann die Position verteidigen. Schreiben Sie mir in PM, wir werden umgehen.
Mir scheint es die bemerkenswerte Phrase